Paper Details

  1. Home
  2. Paper Details

Randomized controlled trial of midazolam premedication to reduce the subjective adverse effects of adenosine.

Author: HouriganC, JacobsI, LockneyA, RogersI, SafihS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Midazolam premedication was found to be safe and effective at reducing the recall of the unpleasant adverse effects of adenosine. There was a significant reduction in the midazolam group for complaint scores of palpitations and chest pain, and a trend to reduction in complaint scores for most other parameters.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine the safety and efficacy of midazolam premedication to minimize the subjective adverse effects of adenosine. METHODS: Double-blind prospective randomized controlled trial of patients presenting to an urban emergency department. Included were a convenience sample of patients w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1442-2026.2001.00178.x

データ提供：米国国立医学図書館（NLM）

Midazolam Premedication to Reduce Adenosine Side Effects

This clinical trial investigates the use of midazolam as a premedication to mitigate the adverse effects of adenosine, a medication commonly used in emergency medicine. The study aimed to determine the safety and efficacy of midazolam in reducing the subjective side effects associated with adenosine administration. The researchers conducted a double-blind randomized controlled trial involving patients presenting to an urban emergency department, comparing the effects of midazolam to a placebo. The goal was to assess the impact of midazolam on reducing the recall of unpleasant side effects after adenosine administration.

Midazolam Effectively Reduces Adenosine-Related Side Effects

The findings of this study demonstrate the effectiveness of midazolam in mitigating the recall of unpleasant side effects associated with adenosine. The study observed a significant reduction in the frequency of palpitations and chest pain among patients who received midazolam compared to those who received a placebo. This highlights the potential of midazolam as a valuable tool for improving the patient experience during adenosine administration.

Easing the Patient Experience

The results suggest that midazolam can help to alleviate the discomfort associated with adenosine administration. This is especially relevant for patients who are particularly anxious or have experienced adverse reactions to adenosine in the past. Just as a cool oasis provides respite in the desert, midazolam can offer a soothing effect, making the experience less daunting for patients.

Dr.Camel's Conclusion

This trial demonstrates the potential of midazolam as a safe and effective premedication for reducing the subjective side effects of adenosine. The findings provide valuable insights into improving patient comfort and enhancing the overall experience during adenosine administration. Like a camel navigating a treacherous desert landscape, healthcare providers can leverage midazolam to help patients overcome the challenges of receiving adenosine treatment.
Date :
  1. Date Completed 2001-08-30
  2. Date Revised 2019-11-05
Further Info :

Pubmed ID

11476413

DOI: Digital Object Identifier

10.1046/j.1442-2026.2001.00178.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.